CARTESIAN THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 24.57 USD | -3.50% |
|
-7.04% | +18.80% |
| May. 24 | Mizuho Securities Starts Cartesian Therapeutics With Buy Rating | MT |
| May. 22 | Cartesian Gets Regenerative Medicine Advanced Therapy Label for Myasthenia Gravis Drug Candidate | MT |
Valuation
| Fiscal Period: December | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Capitalization 1 | 107 | 437.2 | - | - |
| Enterprise Value (EV) 1 | 107 | 169.8 | 60.15 | 176.1 |
| P/E ratio | -0.42 x | -2.59 x | -4.28 x | -4.81 x |
| Yield | - | - | - | - |
| Capitalization / Revenue | 4.11 x | 75.1 x | - | - |
| EV / Revenue | 4.11 x | 29.2 x | - | - |
| EV / EBITDA | - | -2.74 x | -0.63 x | -1.38 x |
| EV / FCF | - | -2.74 x | -0.99 x | -2.2 x |
| FCF Yield | - | -36.5% | -101% | -45.5% |
| Price to Book | - | - | - | - |
| Nbr of stocks (in thousands) | 5,173 | 17,796 | - | - |
| Reference price 2 | 20.68 | 24.57 | 24.57 | 24.57 |
| Announcement Date | 3/7/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net sales 1 | - | 26 | 5.82 | - | - |
| EBITDA 1 | - | - | -62 | -96 | -128 |
| EBIT 1 | - | -86.42 | -56.53 | -74.13 | -129.3 |
| Operating Margin | - | -332.32% | -971.34% | - | - |
| Earnings before Tax (EBT) 1 | -6.455 | -238.7 | -97.2 | -75.89 | -127.5 |
| Net income 1 | -6.455 | -219.7 | -101 | -78.44 | -124.6 |
| Net margin | - | -844.91% | -1,735.91% | - | - |
| EPS 2 | - | -49.80 | -9.478 | -5.742 | -5.110 |
| Free Cash Flow 1 | - | - | -62 | -60.94 | -80.16 |
| FCF margin | - | - | -1,065.29% | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 1/23/24 | 3/7/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|
| Net sales 1 | 5.84 | - | - | - | - | - |
| EBITDA 1 | - | -17 | -15 | -16 | - | - |
| EBIT 1 | -13.35 | -14.5 | -14.42 | -14.58 | -14.75 | -15.12 |
| Operating Margin | -228.56% | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -56.82 | -10.71 | -11.57 | -12.19 | -13.07 | -13.96 |
| Net income 1 | -56.82 | -13.4 | -14.89 | -15.23 | -14.29 | -14.73 |
| Net margin | -973.01% | - | - | - | - | - |
| EPS 2 | -10.50 | -1.270 | -1.205 | -1.178 | -1.700 | -1.700 |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 5/8/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - |
| Net Cash position 1 | - | - | 267 | 377 | 261 |
| Leverage (Debt/EBITDA) | - | - | - | - | - |
| Free Cash Flow 1 | - | - | -62 | -60.9 | -80.2 |
| ROE (net income / shareholders' equity) | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - |
| Assets 1 | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - |
| Capex 1 | - | - | 2 | 1 | 1 |
| Capex / Sales | - | - | 34.36% | - | - |
| Announcement Date | 1/23/24 | 3/7/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
24.57
USD
Average target price
43.75
USD
Spread / Average Target
+78.06%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +18.80% | 437M | |
| +12.30% | 118B | |
| +12.15% | 106B | |
| -8.14% | 23.4B | |
| -1.69% | 21.78B | |
| -10.60% | 18.09B | |
| -41.25% | 16.72B | |
| -15.33% | 15.97B | |
| +5.80% | 14.03B | |
| +28.03% | 11.67B |
- Stock Market
- Equities
- RNAC Stock
- Financials Cartesian Therapeutics, Inc.
